https://phys.org/ en-us Latest news from Memorial Sloan-Kettering Cancer Center A new immunotherapy drug, atezolizumab, has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug represents the first new treatment for this form of the disease in more than 20 years and is expected to have a major impact on bladder cancer—the fifth most common form of cancer and the fourth most common in men. Its benefit appears to be lasting in some patients. https://medicalxpress.com/news/2016-06-fda-game-changer-immunotherapy-drug.html Oncology & Cancer Wed, 01 Jun 2016 08:16:28 EDT news383987769 The lack of participation in clinical research may be the Achilles' heel of today's cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans indicated that they were "likely" to enroll in a clinical trial. Other studies have shown that only 4 percent of cancer patients enroll in clinical trials nationally each year. https://medicalxpress.com/news/2016-05-survey-americans-enroll-clinical-trials.html Oncology & Cancer Tue, 24 May 2016 10:30:01 EDT news383302503 Even after successful treatment, cancer can sometimes come back years later and spread to different organs. This is called latent metastasis. A new study by MSK scientists sheds light on how cancer cells hide out and remain undetected by our immune system, opening up a promising new avenue for treatment. https://medicalxpress.com/news/2016-04-metastatic-cancer-cells-evade-immune.html Oncology & Cancer Fri, 01 Apr 2016 09:40:01 EDT news378719308 Today, the US Food and Drug Administration (FDA) approved the immunotherapy combination nivolumab (Opdivo) plus ipilimumab (Yervoy) for use in patients with metastatic melanoma. This is the first-ever combination immunotherapy to receive approval by the FDA. To learn more, we spoke with Memorial Sloan Kettering medical oncologist and cancer immunologist Jedd Wolchok, the physician-scientist leading this work. https://medicalxpress.com/news/2015-10-immunotherapy-combination-nivolumab-ipilimumab-fda.html Oncology & Cancer Mon, 05 Oct 2015 09:20:01 EDT news363254529 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated. https://medicalxpress.com/news/2015-08-cancer-publish-landmark-basket.html Oncology & Cancer Thu, 20 Aug 2015 09:03:41 EDT news359280197 A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology. https://medicalxpress.com/news/2014-12-kind-drug-leukemia-patients.html Oncology & Cancer Sun, 07 Dec 2014 13:17:43 EST news337180643 In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders. https://medicalxpress.com/news/2014-12-immunotherapy-drugs-outcomes-hodgkin-lymphoma.html Oncology & Cancer Sat, 06 Dec 2014 15:02:44 EST news337100555 In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. The study, led by Craig H. Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology. https://medicalxpress.com/news/2014-12-positive-standard-hodgkin-lymphoma-patients.html Oncology & Cancer Sat, 06 Dec 2014 15:01:38 EST news337100487 Bacterial infections can cause major problems for people undergoing treatment for cancer and other diseases. The concern is especially acute during hospitalization, when patients often have weakened immune function. https://medicalxpress.com/news/2014-10-body-defends-bacteria.html Medical research Thu, 23 Oct 2014 05:33:59 EDT news333261231 Research led by investigators at Memorial Sloan Kettering Cancer Center has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory, giving researchers an exciting new tool to test cancer drugs and personalize cancer treatment. https://medicalxpress.com/news/2014-09-precision-medicine-tool-prostate-cancer.html Oncology & Cancer Thu, 04 Sep 2014 12:00:01 EDT news329050300 Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering's Richard J. O'Reilly, MD, a world-renowned pioneer in the development of transplant protocols. Their review will be published in the July 30 issue of the New England Journal of Medicine. https://medicalxpress.com/news/2014-07-transplantation-shown-highly-effective-immune.html Medical research Wed, 30 Jul 2014 17:10:01 EDT news325954969 New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease. https://medicalxpress.com/news/2014-05-genomic-tumor-lung-cancer-patients.html Oncology & Cancer Tue, 20 May 2014 16:00:06 EDT news319819786 A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago. https://medicalxpress.com/news/2014-05-phase-plx3397-potential-therapy-patients.html Oncology & Cancer Wed, 14 May 2014 17:27:29 EDT news319307238 New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain. Published in the February 27 issue of Cell, the study found that tumor cells that reach the brain—and successfully grow into new tumors—hug capillaries and express specific proteins that overcome the brain's natural defense against metastatic invasion. https://medicalxpress.com/news/2014-02-reveals-mechanisms-cancer-cells-metastatic.html Oncology & Cancer Thu, 27 Feb 2014 13:42:35 EST news312730940 Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine. https://medicalxpress.com/news/2014-02-cell-therapy-remarkable-ability-eradicate.html Oncology & Cancer Wed, 19 Feb 2014 14:00:03 EST news312039105 (Medical Xpress)—Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are working side by side to unravel the mysterious link between obesity and cancer. Most recently, their collaborative effort has yielded an interesting association: Obesity prior to diagnosis is associated with a five-fold increase in the risk of death from early-stage squamous cell carcinoma (SCC) of the tongue. https://medicalxpress.com/news/2014-02-links-obesity-poor-survival-tongue.html Oncology & Cancer Wed, 05 Feb 2014 09:25:24 EST news310814713 (Medical Xpress)—Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that – ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies. https://medicalxpress.com/news/2014-01-newly-monoclonal-antibody-clinical.html Oncology & Cancer Wed, 29 Jan 2014 09:01:50 EST news310208498 Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body. https://medicalxpress.com/news/2013-09-oncogenic-signatures-tcga-personalized-therapy.html Genetics Fri, 27 Sep 2013 13:13:53 EDT news299506420 For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children's Research Hospital, University of Washington, and other institutions. The discovery was reported online today in the journal Nature Genetics. https://medicalxpress.com/news/2013-09-uncover-genetic-childhood-leukemia.html Oncology & Cancer Sun, 08 Sep 2013 13:00:01 EDT news297862643 Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium. https://medicalxpress.com/news/2013-09-mri-surgery-benefit-women-early.html Oncology & Cancer Wed, 04 Sep 2013 17:26:04 EDT news297534355 A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor's pathology could be an important factor doctors use to guide cancer treatment decisions. https://medicalxpress.com/news/2013-08-pattern-lung-cancer-pathology-recurrence.html Oncology & Cancer Wed, 07 Aug 2013 16:29:05 EDT news295111734 (Medical Xpress)—Researchers from Memorial Sloan-Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became publicly available. Their methods, published in this week's Nature Communications, could provide a usable framework for other researchers to better assess cell lines' validity for future use in this and in other types of cancer research. https://medicalxpress.com/news/2013-07-popular-ovarian-cancer-cell-lines.html Oncology & Cancer Mon, 15 Jul 2013 07:37:51 EDT news293092655 Researchers at Memorial Sloan-Kettering Cancer Center, together with collaborators in Germany, have developed a new method for identifying the cell of origin of intracellular and secreted proteins within multicellular environments. https://phys.org/news/2013-07-method-tracking-cell.html Cell & Microbiology Wed, 10 Jul 2013 14:36:22 EDT news292685773 The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). https://medicalxpress.com/news/2013-06-combination-drugs-tumor-responses-advanced.html Oncology & Cancer Sun, 02 Jun 2013 12:21:45 EDT news289394494 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). https://medicalxpress.com/news/2013-06-drug-progression-free-survival-tumors-rare.html Oncology & Cancer Sat, 01 Jun 2013 12:07:16 EDT news289307229 Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells. Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers. https://medicalxpress.com/news/2013-03-monoclonal-antibody-proteins-cancer-cells.html Oncology & Cancer Wed, 13 Mar 2013 14:15:59 EDT news282402953 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. https://medicalxpress.com/news/2013-02-drug-shown-reverse-radioiodine-resistance.html Oncology & Cancer Thu, 14 Feb 2013 02:50:01 EST news280031566 A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer. Their findings were reported online today in Nature Biotechnology. https://medicalxpress.com/news/2012-12-cell-technique-cell-based-immune-therapies.html Oncology & Cancer Sun, 16 Dec 2012 13:00:20 EST news274884184 Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma. https://medicalxpress.com/news/2012-05-mutations-squamous-cell-lung-cancer.html Oncology & Cancer Thu, 17 May 2012 09:49:49 EDT news256466911